Pharmacokinetics, tissue distribution, metabolism, and excretion of depside salts from Salvia miltiorrhiza in rats

被引:55
作者
Li, Xiaochuan
Yu, Chen
Lu, Youli
Gu, Yunlong
Lu, Jie
Xu, Wei
Xuan, Lijiang
Wang, Yiping [1 ]
机构
[1] Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
[2] Shanghai Xuhui Cent Hosp, Cent Lab, Shanghai, Peoples R China
关键词
D O I
10.1124/dmd.106.013045
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Salviae miltiorrhiza, a traditional Chinese medical herb known as "Danshen," has been widely used in clinics to improve blood circulation, relieve blood stasis, and treat coronary heart disease. Depside salts from S. miltiorrhiza are a novel drug in which magnesium lithospermate B and its analogs are the active components. The pharmacokinetics, tissue distribution, metabolism, and excretion of three of the major components, lithospermic acid B, rosmarinic acid ( RA), and lithospermic acid ( LA), were studied by liquid chromatography-tandem mass spectrometry following intravenous administration in Sprague-Dawley rats. The elimination half-lives for LSB, RA, and LA were 1.04, 0.75, and 2.0 h, respectively, when 60 mg/kg S. miltiorrhiza depside salts were administrated. The areas under the curve for LSB, RA, and LA were 51.6, 6.6, and 25.2 mg center dot h/l, respectively, and the values decreased in the individual tissues in the following order: kidney > lung > liver > heart > spleen > brain for LSB; kidney > lung > heart > liver > spleen > brain for RA; and heart > lung > kidney > liver > spleen > brain for LA. After intravenous administration of 60 mg/kg S. miltiorrhiza depside salts, 86% of the LSB was excreted in the bile within 6 h. The main metabolites M1 and M2 were found in the serum. Overall, the results show that depside salts from S. miltiorrhiza are rapidly and widely distributed to tissues after intravenous administration in rats but that they are also rapidly cleared and excreted.
引用
收藏
页码:234 / 239
页数:6
相关论文
共 20 条
[1]   Isolation of two highly potent and non-toxic inhibitors of human immunodeficiency virus type 1 (HIV-1) integrase from Salvia miltiorrhiza [J].
Abd-Elazem, IS ;
Chen, HS ;
Bates, RB ;
Huang, RCC .
ANTIVIRAL RESEARCH, 2002, 55 (01) :91-106
[2]   Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans [J].
Baba, S ;
Osakabe, N ;
Natsume, M ;
Yasuda, A ;
Muto, Y ;
Hiyoshi, K ;
Takano, H ;
Yoshikawa, T ;
Terao, J .
EUROPEAN JOURNAL OF NUTRITION, 2005, 44 (01) :1-9
[3]   Orally administered rosmarinic acid is present as the conjugated and/or methylated forms in plasma, and is degraded and metabolized to conjugated forms of caffeic acid, ferulic acid and m-coumaric acid [J].
Baba, S ;
Osakabe, N ;
Natsume, M ;
Terao, J .
LIFE SCIENCES, 2004, 75 (02) :165-178
[4]   Inhibitory effect of caffeic acid analogues isolated from Salviae Miltiorrhizae Radix against 1,1-diphenyl-2-picrylhydrazyl radical [J].
Chen, CP ;
Yokozawa, T ;
Chung, HY .
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, 1999, 51 (01) :59-63
[5]   DEMONSTRATION OF THE MYOCARDIAL SALVAGE EFFECT OF LITHOSPERMIC ACID-B ISOLATED FROM THE AQUEOUS EXTRACT OF SALVIA-MILTIORRHIZA [J].
FUNG, KP ;
ZENG, LH ;
WU, J ;
WONG, HNC ;
LEE, CM ;
HON, PM ;
CHANG, HM ;
WU, TW .
LIFE SCIENCES, 1993, 52 (22) :PL239-PL244
[6]   Preventive effect of lithospermate B from Salvia miltiorhiza on experimental hepatitis induced by carbon tetrachloride or D-galactosamine/lipopolysaccharide [J].
Hase, K ;
Kasimu, R ;
Basnet, P ;
Kadota, S ;
Namba, T .
PLANTA MEDICA, 1997, 63 (01) :22-26
[7]  
Kasimu R, 1998, CHEM PHARM BULL, V46, P500, DOI 10.1248/cpb.46.500
[8]   Biologically active components from traditional Chinese medicines [J].
Li, LN .
PURE AND APPLIED CHEMISTRY, 1998, 70 (03) :547-554
[9]   Simultaneous determination of magnesium lithospermate B, rosmarinic acid, and lithospermic acid in beagle dog serum by liquid chromatography/tandem mass spectrometry [J].
Li, XC ;
Yu, C ;
Sun, WK ;
Liu, GY ;
Jia, JY ;
Wang, YP .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2004, 18 (23) :2878-2882
[10]  
Li XC, 2004, ACTA PHARMACOL SIN, V25, P1402